Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities

Supportive Care in Cancer

Volumn 19, Issue 8, 2011, Pages 1079-1095

  Lacouture, Mario E ^a   Anadkat, Milan J ^b   Bensadoun, René Jean ^c   Bryce, Jane ^d   Chan, Alexandre ^e   Epstein, Joel B ^f   Eaby Sandy, Beth ^g   Murphy, Barbara A ^h  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c POITIERS UNIVERSITY HOSPITAL   (France)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^f UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

EGFR inhibitors; Mucositis; Paronychia; Pruritus; Radiation dermatitis; Rash; Recommendations; Xerosis

Indexed keywords

ALCLOMETASONE; BECLOMETASONE; BETAMETHASONE; CETUXIMAB; CLINDAMYCIN; CORTICOSTEROID; DIPHENHYDRAMINE; DOXYCYCLINE; EFLORNITHINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOCINONIDE; GABAPENTIN; HYDROCORTISONE; HYDROXYZINE; ISOTRETINOIN; LORATADINE; MENADIONE; METHYLPREDNISOLONE; MINOCYCLINE; MINOXIDIL; MOMETASONE FUROATE; MONOCLONAL ANTIBODY; PENTOXIFYLLINE; PLACEBO; PREGABALIN; PROTEIN TYROSINE KINASE INHIBITOR; SUNSCREEN; UNINDEXED DRUG; ZINC;

ACNE; AGE DISTRIBUTION; ALOPECIA; ATOPIC DERMATITIS; CANCER RADIOTHERAPY; CLINICAL FEATURE; CRYOTHERAPY; DERMATITIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DRUG TREATMENT FAILURE; ESTHETIC SURGERY; HAIR DISEASE; HAIR GROWTH; HAIR LOSS; HEAD AND NECK CANCER; HIRSUTISM; HUMAN; HYPERTRICHOSIS; LOW DRUG DOSE; LOW LEVEL LASER THERAPY; MONOTHERAPY; MUCOSA INFLAMMATION; ORAL MUCOSAL DISEASE; PAPULOPUSTULAR RASH; PAPULOPUSTURAL RASH; PARONYCHIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN SECRETION; PRURITUS; QUALITY OF LIFE; RADIATION DERMATITIS; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; RISK REDUCTION; SEDATION; SEX RATIO; SIDE EFFECT; SKIN FISSURE; SKIN MANIFESTATION; SKIN TOXICITY; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; TRICHOMEGALY; URTICARIA; VITAMIN SUPPLEMENTATION; XEROSIS; XEROSTOMIA;

EID: 84984568870     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-011-1197-6     Document Type: Review

References (114)

1. Y Balagula C Garbe P Myskowski A Hauschild B Rapoport CB Boers-Doets ME Lacouture 2011 Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors Int J Dermatol 50 129 146 21244375 1:CAS:528:DC%2BC3MXisF2hurk%3D
2. SL Boone A Rademaker D Liu C Pfeiffer DJ Mauro ME Lacouture 2007 Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results Oncology 72 3-4 152 159 18160805 1:CAS:528:DC%2BD1cXptlKlug%3D%3D (Pubitemid 351161602)
3. M Somerfield J Padberg D Pfister, et al. 2000 ASCO clinical practice guidelines: process, progress, pitfalls, and prospects Classic Papers Curr Comments 4 881 886
4. ME Lacouture 2006 Mechanisms of cutaneous toxicities to EGFR inhibitors Nat Rev Cancer 6 10 803 812 16990857 1:CAS:528:DC%2BD28XpvVClsr4%3D (Pubitemid 44450468)
5. JC Hassel M Kripp S Al-Batran RD Hofheinz 2010 Treatment of epidermal growth factor receptor antagonist-induced skin rash: results of a survey among German oncologists Onkologie 33 3 94 98 20215799 1:CAS:528:DC%2BC3cXivFGgs74%3D
6. Jatoi A, Dakhil SR, Sloan JA, Kugler JW, Rowland KM Jr, Schaefer PL, Novotny PJ, Wender DB, Gross HM, Loprinzi CL (2010) Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB). Support Care Cancer (in press)
7. A Jatoi A Thrower JA Sloan PJ Flynn NL Wentworth-Hartung SR Dakhil BI Mattar DA Nikcevich P Novotny A Sekulic CL Loprinzi 2010 Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4) Oncologist 15 9 1016 1022 20798191
8. A Jatoi K Rowland JA Sloan HM Gross PA Fishkin SP Kahanic PJ Novotny PL Schaefer DB Johnson LK Tschetter CL Loprinzi 2008 Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB) Cancer 113 4 847 853 18543329 1:CAS:528:DC%2BD1cXhtVGhsbbP
9. A Scope JA Lieb SW Dusza DL Phelan PL Myskowski L Saltz AC Halpern 2009 A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption J Am Acad Dermatol 61 4 614 620 19646778 1:CAS:528: DC%2BD1MXhtlWks7zP
10. ME Lacouture EP Mitchell B Piperdi MV Pillai H Shearer N Iannotti F Xu M Yassine 2010 Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer J Clin Oncol 28 8 1351 1357 20142600 1:CAS:528:DC%2BC3cXksFSqtbc%3D
11. A Scope AL Agero SW Dusza PL Myskowski JA Lieb L Saltz NE Kemeny AC Halpern 2007 Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption J Clin Oncol 25 34 5390 5396 18048820 1:CAS:528:DC%2BD1cXnvVCjtA%3D%3D (Pubitemid 350232214)
12. K Katzer J Tietze E Klein V Heinemann T Ruzicka A Wollenberg 2010 Topical therapy with nadifloxacin cream and prednicarbate cream improves acneiform eruptions caused by the EGFR-inhibitor cetuximab-a report of 29 patients Eur J Dermatol 20 1 82 84 19797039 1:CAS:528:DC%2BC3cXitlKqsr4%3D
13. Perez-Soler R, Zou Y, Li T, Tornos C, Ling Y (2006) Topical vitamin K3 (Vit K3, Menadione) prevents erlotinib and cetuximab-induced EGFR inhibition in the skin. J Clin Oncol ASCO Annual Meeting Proceedings part I, vol. 24, no. 18S (June 20 Supplement)
14. Radovics N, Kornek G, Thalhammer F, Weihsengruber F, Pietrzak C, Resch G, Petzer AL, Hauser I, Wogritsch C, Greil R (2010) Analysis of the effects of vitamin K1 cream on cetuximab-induced acne-like rash. J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition) 28:15S (May 20 Supplement)
15. P Bidoli DL Cortinovis I Colombo A Crippa F Cicchiello F Villa ME Cazzaniga G Altomare 2010 Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer J Thorac Oncol 5 10 1662 1663 20871265
16. P Vezzoli AV Marzano F Onida E Alessi B Galassi M Tomirotti E Berti 2008 Cetuximab-induced acneiform eruption and the response to isotretinoin Acta Derm Venereol 88 1 84 86 18176767 (Pubitemid 351212152)
17. R Gutzmer T Werfel R Mao A Kapp J Elsner 2005 Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy Br J Dermatol 153 4 849 851 16181478 1:STN:280:DC%2BD2MrgvFKhsA%3D%3D (Pubitemid 41415923)
18. EA Olsen D Whiting W Bergfeld J Miller M Hordinsky R Wanser P Zhang B Kohut 2007 A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men J Am Acad Dermatol 57 5 767 774 17761356 (Pubitemid 47553065)
19. EA Olsen FE Dunlap T Funicella JA Koperski JM Swinehart EH Tschen RJ Trancik 2002 A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men J Am Acad Dermatol 47 3 377 385 12196747
20. AW Lucky DJ Piacquadio CM Ditre F Dunlap I Kantor AG Pandya RC Savin MD Tharp 2004 A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss J Am Acad Dermatol 50 4 541 553 15034503 (Pubitemid 38393163)
21. B Burtness M Anadkat S Basti, et al. 2009 NCCN Task Force Report: management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer J Natl Compr Canc 7 S1 s5 s21
22. J Ocvirk S Cencelj 2010 Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer JEADV 24 453 459 19793151 1:CAS:528:DC%2BC3cXlslWlsr0%3D
23. R Hoffmann 2008 A 4-month, open-label study evaluating the efficacy of eflornithine 11.5% creamin the treatment of unwanted facial hair in women using TrichoScan Eur J Dermatol 18 1 65 70 18086592 1:CAS:528:DC%2BD1cXjtFejtLY%3D (Pubitemid 351158175)
24. J Jackson JJ Caro G Caro F Garfield F Huber W Zhou CS Lin D Shander K Schrode Eflornithine HCl Study Group 2007 The effect of eflornithine 13.9% cream on the bother and discomfort due tohirsutism Int J Dermatol 46 9 976 981 17822506 1:CAS:528:DC%2BD2sXhtF2htr%2FK (Pubitemid 47382290)
25. SP Amin DJ Goldberg 2006 Clinical comparison of four hair removal lasers and light sources J Cosmet Laser Ther 8 2 65 68 16766483
26. I Hamzavi E Tan J Shapiro H Lui 2007 A randomized bilateral vehicle-controlled study of eflornithine cream combined with laser treatment versus laser treatment alone for facial hirsutism in women J Am Acad Dermatol 57 1 54 59 17270315 (Pubitemid 46899263)
27. SR Smith DJ Piacquadio B Beger C Littler 2006 Eflornithine cream combined with laser therapy in the management of unwanted facial hair growth in women: a randomized trial Dermatol Surg 32 10 1237 1243 17034372 1:CAS:528: DC%2BD2sXivFSisw%3D%3D (Pubitemid 44569994)
28. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Available at http://ctep.cancer.gov/forms/CTCAEv3.pdf
29. IR Campbell MH Illingworth 1992 Can patients wash during radiotherapy to the breast or chest wall? A randomized controlled trial Clin Oncol (R Coll Radiol) 4 78 82 1:STN:280:DyaK383gslyhsA%3D%3D
30. I Roy A Fortin M Larochelle 2001 The impact of skin washing with water and soap during breast irradiation: a randomized study Radiother Oncol 58 333 339 11230896 1:STN:280:DC%2BD3M3mtVWhsQ%3D%3D (Pubitemid 32181869)
31. N Salvo E Barnes J van Draanen E Stacey G Mitera D Breen A Giotis G Czarnota J Pang C De Angelis 2010 Prophylaxis and management of acute radiation-induced skin reactions: a systematic review of the literature Curr Oncol 17 4 94 112 20697521 1:STN:280:DC%2BC3cjjs1Whuw%3D%3D
32. RC Miller DJ Schwartz JA Sloan PC Griffin RL Deming JC Anders TJ Stoffel RE Haselow PL Schaefer JD Bearden 3rd PJ Atherton CL Loprinzi JA Martenson 2010 Mometasone furoate effect on acute skin toxicity in breast cancer patients receiving radiotherapy: a phase III double-blind, randomized trial from the North Central Cancer Treatment Group N06C4 Int J Radiat Oncol Biol Phys 79 1460 1466 20800381
33. EA Elliott JR Wright RS Swann, et al. 2006 Phase III trial of an emulsion containing trolamine for the prevention of radiation dermatitis in patients with advanced squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Trial 99-13 J Clin Oncol 24 2092 2097 16648511 1:CAS:528:DC%2BD28Xlt1amu7w%3D (Pubitemid 46622120)
34. E Aygenc S Celikkanat M Kaymakci, et al. 2004 Prophylactic effect of pentoxifylline on radiotherapy complications: a clinical study Otolaryngol Head Neck Surg 130 351 356 15054378 (Pubitemid 38451396)
35. LC Lin J Que LK Lin FC Lin 2006 Zinc supplementation to improve mucositis and dermatitis in patients after radiotherapy for head-and-neck cancers: a double-blind, randomized study Int J Radiat Oncol Biol Phys 65 745 750 16751063 1:CAS:528:DC%2BD28XltlGrtb0%3D (Pubitemid 43810226)
36. S Segaert E Van Cutsem 2005 Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors Ann Oncol 16 1425 1433 16012181 1:STN:280:DC%2BD2MvjvVaiuw%3D%3D (Pubitemid 41222414)
37. S Segaert J Tabernero O Chosidow, et al. 2005 The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies J Dtsch Dermatol Ges 3 599 606 16033478 (Pubitemid 41647826)
38. E Roé MP García Muret E Marcuello J Capdevila C Pallarés A Alomar 2006 Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients J Am Acad Dermatol 55 429 437 16908348 (Pubitemid 44189595)
39. P Racca L Fanchini V Caliendo, et al. 2008 Efficacy and skin toxicity management with cetuximab in metastatic colorectal cancer: outcomes from an Oncologic/Dermatologic Cooperation Clin Colorectal Cancer 7 48 54 18279577 1:CAS:528:DC%2BD1cXislGisrY%3D (Pubitemid 351252451)
40. EW Monroe DI Bernstein RW Fox, et al. 1992 Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria Arzneimittelforschung 42 1119 1121 1445478 1:STN:280:DyaK3s%2FnsFeksA%3D%3D
41. EW Monroe 1992 Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria and atopic dermatitis Clin Ther 14 1 17 21 1349509 1:STN:280:DyaK383kvVKgsQ%3D%3D
42. G Porzio F Aielli L Verna C Porto M Tudini K Cannita C Ficorella 2006 Efficacy of pregabalin in the management of cetuximab-related itch J Pain Symptom Manage 32 397 398 17085262 (Pubitemid 44666299)
43. I Goutos M Eldardiri AA Khan P Dziewulski PM Richardson 2010 Comparative evaluation of antipruritic protocols in acute burns. The emerging value of gabapentin in the treatment of burns pruritus J Burn Care Res 31 1 57 63 20061838
44. AI Gunal G Ozalp TK Yoldas SY Gunal E Kirciman H Celiker 2004 Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial Nephrol Dial Transplant 19 12 3137 3139 15575002 1:CAS:528:DC%2BD2cXhtVCrsrbN (Pubitemid 40063517)
45. B Vincenzi G Tonini D Santini 2010 Aprepitant for erlotinib-induced pruritus N Engl J Med 363 397 398 20660413 1:CAS:528:DC%2BC3cXptFWjsb8%3D
46. B Bromm E Scharein U Darsow J Ring 1995 Effects of menthol and cold on histamine-induced itch and skin reactions in man Neurosci Lett 187 157 160 7624016 1:CAS:528:DyaK2MXkvValtLo%3D
47. LA Drake LE Millikan 1995 The antipruritic effect of 5% doxepin cream in patients with eczematous dermatitis. Doxepin Study Group Arch Dermatol 131 12 1403 1408 7492129 1:CAS:528:DyaK28XmvFamuw%3D%3D
48. M Shohrati SM Davoudi S Keshavarz B Sadr A Tajik 2007 Cetirizine, doxepine, and hydroxyzine in the treatment of pruritus due to sulfur mustard: a randomized clinical trial Cutan Ocul Toxicol 26 3 249 255 17687689 1:CAS:528:DC%2BD2sXos12nurs%3D (Pubitemid 47237802)
49. F Pour-Reza-Gholi A Nasrollahi A Firouzan E Nasli Esfahani F Farrokhi 2007 Low-dose doxepin for treatment of pruritus in patients on hemodialysis Iran J Kidney Dis 1 1 34 37 19357442
50. DC Eschler PA Klein 2010 An evidence-based review of the efficacy of topical antihistamines in the relief of pruritus J Drugs Dermatol 9 8 992 997 20684150
51. SJ Yaffe, et al. 1973 Antihistamine in topical preparations Pediatrics 51 299 301
52. D Khuntia J Harris SM Bentzen, et al. 2008 Increased oral mucositis after IMRT versus non-IMRT when combined with cetuximab and cisplatin or docetaxel for head and neck cancer: preliminary results of RTOG 0234 Int J Radiat Oncol Biol Phys 72 1 S33
53. RJ Motzer R Amato M Todd, et al. 2003 Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma Invest New Drugs 21 1 99 101 12795534 1:CAS:528:DC%2BD3sXisVGjtL0%3D (Pubitemid 36628489)
54. HQ Xiong A Rosenberg A LoBuglio, et al. 2004 Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial J Clin Oncol 22 13 2610 2616 15226328 1:CAS:528:DC%2BD2cXpsVWksLY%3D (Pubitemid 41103748)
55. LB Saltz NJ Meropol PJ Loehrer MN Needle J Kopit RJ Mayer 2004 Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor J Clin Oncol 22 7 1201 1208 14993230 1:CAS:528:DC%2BD2cXpsVGktLw%3D (Pubitemid 41079832)
56. NA Reynolds AJ Wagstaff 2004 Cetuximab-in the treatment of metastatic colorectal cancer Drugs 64 1 109 118 14723561 1:CAS:528:DC%2BD2cXhs1SmsL0%3D (Pubitemid 38125631)
57. JB Vermorken J Trigo R Hitt, et al. 2007 Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy J Clin Oncol 25 16 2171 2177 17538161 1:CAS:528:DC%2BD2sXnsVShtrk%3D (Pubitemid 46954639)
58. CP Belani MT Schreeder RG Steis, et al. 2008 Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study Cancer 113 9 2512 2517 18816622 1:CAS:528:DC%2BD1cXhtlKru77E
59. JB Vermorken R Mesia F Rivera, et al. 2008 Platinum-based chemotherapy plus cetuximab in head and neck cancer New Engl J Med 359 11 1116 1127 18784101 1:CAS:528:DC%2BD1cXhtFWrsrnI
60. M Thomas 2005 Cetuximab: adverse event profile and recommendations for toxicitmanagement Clin J Oncol Nurs 9 3 332 338 15973844
61. HJ Lenz 2006 Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events Oncology 20 5 Suppl 2 5 13 16736978
62. DM Keefe MM Schubert LS Elting S St JB Epstein JE Raber-Drulacher, et al. 2007 Updated clinical practice guidelines for the prevention and treatment of mucostis Cancer 109 5 820 831 17236223 1:CAS:528:DC%2BD2sXjsVKns7o%3D (Pubitemid 46335677)
63. EB Rubenstein DE Peterson M Schubert D Keefe D McGuire J Epstein, et al. 2004 Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis Cancer 100 9 2026 2046 15108223 (Pubitemid 38525884)
64. JB Epstein S Elad E Eliav R Jurevic R Benoliel 2007 Orofacial pain in cancer: part II: clinical perspectives and management J Dent Res 86 6 506 518 17525349 1:STN:280:DC%2BD2szhtleitw%3D%3D
65. M Gorsky J Epstein A Raviv R Yaniv E Truelove 2008 Topical minocycline for managing symptoms of recurrent aphthous stomatitis Spec Care Dent 28 1 27 31
66. M Gorsky JB Epstein R Sl H Elishoov N Yarom 2007 Topical minocycline and tetracycline rinses in treatment of recurrent aphthous stomatitis: a randomized cross-over study Dermatol Online J 13 2 1 17498420
67. S Tsimboukis I Merikas EM Karapanagiotou MW Saif KN Syrigos 2009 Erlotinib-induced skin rash in patients with non-small-cell lung cancer: pathogenesis, clinical significance, and management Clin Lung Cancer 10 2 106 111 19362953 1:CAS:528:DC%2BD1MXltFers70%3D
68. JC Hu P Sadeghi LC Pinter-Brown S Yashar MW Chiu 2007 Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management J Am Acad Dermatol 56 2 317 326 17141360 (Pubitemid 46091817)
69. S Ricciardi S Tomao F de Marinis 2009 Toxicity of targeted therapy in non-small-cell lung cancer management Clin Lung Cancer 10 1 28 35 19289369 1:CAS:528:DC%2BD1MXjslalu70%3D
70. MW Saif K Kaley L Lamb J Pecerillo S Hotchkiss L Steven M Brennan R Penney C Gillespie W Shaib 2010 Management of skin toxicities of anti-EGFR agents in patients with pancreatic cancer and other GI tumors by using electronic communication: effective and convenient JOP 11 2 176 182 20208331
71. R Gutzmer T Werfel A Kapp J Elsner 2006 Cutaneous side effects of EGF-receptor inhibition and their management Hautarzt 57 6 509 513 16205868 1:STN:280:DC%2BD28zjtVOiug%3D%3D (Pubitemid 43891893)
72. R Pérez-Soler JP Delord A Halpern K Kelly J Krueger BM Sureda J von Pawel J Temel S Siena D Soulières L Saltz J Leyden 2005 HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum Oncologist 10 5 345 356 15851793 (Pubitemid 40647253)
73. A Wollenberg J Kroth A Hauschild T Dirschka 2010 Cutaneous side effects of EGFR inhibitors-appearance and management Dtsch Med Wochenschr 135 4 149 154 20101558 1:STN:280:DC%2BC3c%2FlsVKltg%3D%3D
74. NT Shah MG Kris W Pao LB Tyson BM Pizzo MH Heinemann L Ben-Porat DL Sachs RT Heelan VA Miller 2005 Practical management of patients with non-small-cell lung cancer treated with gefitinib J Clin Oncol 23 1 165 174 15557594 1:CAS:528:DC%2BD2MXpslakug%3D%3D (Pubitemid 41702635)
75. MB Jennings D Alfieri K Ward C Lesczczynski 1998 Comparison of salicylic acid and urea versus ammonium lactate for the treatment of foot xerosis. A randomized, double-blind, clinical study J Am Podiatr Med Assoc 88 7 332 336 9680769 1:STN:280:DyaK1czksFOnsw%3D%3D (Pubitemid 128685929)
76. KJ Busam P Capodieci R Motzer T Kiehn D Phelan AC Halpern 2001 Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225 Br J Dermatol 144 6 1169 1176 11422037 1:CAS:528:DC%2BD3MXltFeiu7c%3D (Pubitemid 34204207)
77. A Becker A van Wijk EF Smit PE Postmus 2010 Side-effects of long-term administration of erlotinib in patients with non-small cell lung cancer J Thorac Oncol 5 9 1477 1480 20736807
78. OSI Pharmaceuticals (2005) Tarceva package insert
79. ImClone Systems (2006) Erbitux package insert
80. A Osio C Mateus JC Soria C Massard D Malka V Boige B Besse C Robert 2009 Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors Br J Dermatol 161 3 515 521 19466958 1:STN:280:DC%2BD1MrnsleltQ%3D%3D
81. SH Hong CW Wong ML Privalsky 1998 Signaling by tyrosine kinases negatively regulates the interaction between transcription factors and SMRT (silencing mediator of retinoic acid and thyroid hormone receptor) corepressor Mol Endocrinol 12 1161 1171 9717842 1:CAS:528:DyaK1cXltFykurk%3D (Pubitemid 30659043)
82. R Baran 1986 Etretinate and the nails (study of 130 cases) possible mechanisms of some side-effects Clin Exp Dermatol 11 148 152 3720014 1:STN:280:DyaL283ksFOhsA%3D%3D (Pubitemid 16167382)
83. F Bouscarat C Bouchard D Bouhour 1998 Paronychia and pyogenic granuloma of the great toes in patients treated with indinavir N Engl J Med 338 1776 1777 9625645 1:STN:280:DyaK1c3nt1elug%3D%3D (Pubitemid 28268602)
84. LM Sassone RA Fidel CF Murad SR Fidel R Hirata Jr 2008 Antimicrobial activity of sodium hypochlorite and chlorhexidine by two different tests Aust Endod J 34 1 19 24 18352899
85. T Eames B Grabein J Kroth A Wollenberg 2010 Microbiological analysis of epidermal growth factor receptor inhibitor therapy-associated paronychia J Eur Acad Dermatol Venereol 24 8 958 960 20015177 1:CAS:528:DC%2BC3cXhtFers7rE
86. GL Floersheim 1989 Treatment of brittle fingernails with biotin Z Hautkr 64 1 41 48 2648686 1:STN:280:DyaL1M7ovV2jug%3D%3D
87. A Tosti BM Piraccini E Ghetti MD Colombo 2002 Topical steroids versus systemic antifungals in the treatment of chronic paronychia: an open, randomized double-blind and double dummy study J Am Acad Dermatol 47 1 73 76 12077585
88. U Wollina 2001 Acute paronychia: comparative treatment with topical antibiotic alone or in combination with corticosteroid J Eur Acad Dermatol Venereol 15 1 82 84 11451337 1:STN:280:DC%2BD38%2FitFWlsw%3D%3D (Pubitemid 32842787)
89. A Rao C Bunker 2010 Efficacy and safety of tacrolimus ointment 0.1% vs. betamethasone 17-valerate 0.1% in the treatment of chronic paronychia: an unblinded randomized study Br J Dermatol 163 1 208 20353455 1:STN:280: DC%2BC3cjgslWhug%3D%3D
90. D Rigopoulos S Gregoriou E Belyayeva G Larios G Ontochristopoulos A Katsambas 2009 Efficacy and safety of tacrolimus ointment 0.1% vs. betamethasone 17-valerate 0.1% in the treatment of chronic paronychia: an unblinded randomized study Br J Dermatol 160 4 858 860 19120329 1:CAS:528: DC%2BD1MXlt1Gmt78%3D
91. CR Daniel 3rd MP Daniel CM Daniel S Sullivan G Ellis 1996 Chronic paronychia and onycholysis: a thirteen-year experience Cutis 58 397 401 8970776 (Pubitemid 26424682)
92. D Rosenbaum D Merenstein F Meyer 2002 Topical steroids more effective than antifungals for chronic paronychia J Fam Pract 51 824 12401149
93. DT Roberts MD Richardson PK Dwyer R Donegan 1992 Terbinafine in chronic paronychia and candida onychomycosis J Derm Treat S1 39 42
94. WA Rutala DJ Weber 1997 Uses of inorganic hypochlorite (bleach) in health-care facilities Clin Microbiol Rev 10 4 597 610 9336664 1:CAS:528:DyaK2sXmvFyhu7s%3D (Pubitemid 27477727)
95. KY Shu HL Kindler M Medenica M Lacouture 2006 Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab Br J Dermatol 154 1 191 192 16403122 (Pubitemid 43381348)
96. BJ Wilhelmi TA Calianos II EA Appelt ME Ortiz JP Heggers LG Phillips 1999 Modified Dakin's solution for cutaneous vibrio infections Ann Plast Surg 43 4 386 389 10517465 1:STN:280:DyaK1MvksFSmsQ%3D%3D (Pubitemid 29463777)
97. WA Rutala EC Cole CA Thomann DJ Weber 1998 Stability and bactericidal activity of chlorine solutions Infect Control Hosp Epidemiol 19 5 323 327 9613692 1:STN:280:DyaK1c3ntlOnug%3D%3D (Pubitemid 128472217)
98. HM Quitkin MP Rosenwasser RJ Strauch 2003 The efficacy of silver nitrate cauterization for pyogenic granuloma of the hand J Hand Surg Am 28 3 435 438 12772100 (Pubitemid 36617798)
99. SZ Ghodsi M Raziei A Taheri M Karami P Mansoori F Farnaghi 2006 Comparison of cryotherapy and curettage for the treatment of pyogenic granuloma: a randomized trial Br J Dermatol 154 4 671 675 16536810 1:STN:280: DC%2BD287ksl2hsQ%3D%3D (Pubitemid 43374092)
100. L Saltz MS Rubin H Hochster, et al. 2001 Acne-like rash predicts response in patients treated with cetuximab (IMC-C225) plus irinotecan (CPT-11) in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor Clin Cancer Res 7 3766s (abstract 559)
101. SM Bentzen A Trotti 2007 Evaluation of early and late toxicities in chemoradiation trials J Clin Oncol 25 26 4096 4103 17827459 1:CAS:528: DC%2BD2sXhtlKqsbrJ (Pubitemid 47492954)
102. A Lièvre JB Bachet V Boige A Cayre D Le Corre E Buc M Ychou O Bouché B Landi C Louvet T André F Bibeau MD Diebold P Rougier M Ducreux G Tomasic JF Emile F Penault-Llorca P Laurent-Puig 2008 KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab J Clin Oncol 26 3 374 379 18202412 (Pubitemid 351171687)
103. HJ Lenz E Van Cutsem S Khambata-Ford RJ Mayer P Gold P Stella B Mirtsching AL Cohn AW Pippas N Azarnia Z Tsuchihashi DJ Mauro EK Rowinsky 2006 Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluropyrimidines J Clin Oncol 24 30 4814 4921
104. D Soulieres NN Senzer EE Vokes M Hidalgo SS Agarwala LL Siu 2004 Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck J Clin Oncol 22 1 77 85 14701768 1:CAS:528:DC%2BD2cXpsVKiurk%3D (Pubitemid 41095117)
105. DM Jackman BY Yeap NI Lindeman P Fidias MS Rabin J Temel AT Skarin M Meyerson AJ Holmes AM Borras B Freidlin PA Ostler J Lucca TJ Lynch BE Johnson PA Jänne 2007 Phase II clinical trial of chemotherapy-naive patients ≥70 years of age treated with erlotinib for advanced non-small-cell lung cancer J Clin Oncol 29 7 760 766 (Pubitemid 350002874)
106. HL West WA Franklin J McCoy PH Gumerlock R Vance DH Lau K Chansky JJ Crowley DR Gandara 2006 Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126 J Clin Oncol 24 12 1807 1813 16622257 1:CAS:528:DC%2BD28XkvVajt70%3D (Pubitemid 46638977)
107. EE Cohen MA Kane MA List BE Brockstein B Mehrotra D Huo AM Mauer C Pierce A Dekker EE Vokes 2005 Phase II trial of gefitinib 250 mg po daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck Clin Cancer Res 11 23 8418 8424 16322304 1:CAS:528:DC%2BD2MXht1KjsrbP (Pubitemid 41746956)
108. NJ Meropol J Berlin JR Hecht, et al. 2003 Multicenter study of ABX-EGF monotherapy in patients with metastatic colorectal cancer Proc Am Soc Clin Oncol 22 256
109. R Pérez-Soler A Chachoua LA Hammond EK Rowinsky M Huberman D Karp J Rigas GM Clark P Santabárbara P Bonomi 2004 Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer J Clin Oncol 22 16 3238 3247 15310767 (Pubitemid 41103678)
110. RS Herbst G Giaccone JH Schiller RB Natale V Miller C Manegold G Scagliotti R Rosell I Oliff JA Reeves MK Wolf AD Krebs SD Averbuch JS Ochs J Grous A Fandi DH Johnson 2004 Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2 J Clin Oncol 22 5 785 794 14990633 1:CAS:528:DC%2BD2cXpsVKjur0%3D (Pubitemid 41103589)
111. ME Lacouture ML Maitland S Segaert A Setser R Baran LP Fox JB Epstein A Barasch L Einhorn L Wagner DP West BL Rapoport MG Kris E Basch B Eaby S Kurtin EA Olsen A Chen JE Dancey A Trotti 2010 A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group Support Care Cancer 18 509 522 20145956
112. MASCC EGFR Inhibitor Skin Toxicity Tool (MESTT). Available at http://www.mascc.org/mc/page.do?sitePageId=98483
113. NCI Common Terminology Criteria for Adverse Events v4.03 (CTCAE). Available at http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14- QuickReference-8.5x11.pdf
114. Chan A, Tan EH (2010) How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors? Support Care Cancer (in press)